On October 13, BioNTech announced that, in a trial of BNT113 in HPV16-positive head and neck cancer, the combination with pembrolizumab did not demonstrate statistically significant superiority in progression-free survival over pembrolizumab alone. BNT113 is an mRNA product designed to stimulate immune responses against antigens derived from HPV16.

Evaluation of overall survival, specified from the outset as the other primary endpoint, will continue. This is not a change of endpoint made after seeing the result. Detailed data have not yet been disclosed, so it is too early to explain why the combination did not succeed on this endpoint. Our article on combination development ↗ should accumulate actual outcomes, not just expectations. BioNTech announcement ↗

Keep following this topic

v2 ·

Investing in another company's drug to advance your own

The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.

  1. PFS result announcedRecorded
  2. Prespecified OS assessmentUnverified
  3. Detailed resultsUnverified
NEXT CHECK

The planned OS analysis, detailed PFS results, and explanations of the population and safety findings.

Hypothesis and what would change it

Even with a plausible complementary mechanism, comparisons of clinical benefit are needed to justify additional costs and risks.

What would change our view: Record the relevant conditions if later analyses show benefit; otherwise revise expectations for this combination without extending the result indiscriminately to other products.

Detailed effect estimates are not public, so the reason for the result and efficacy of mRNA cancer immunotherapy as a class cannot be concluded. OS was not added after the result. The trial report does not establish intercompany partnership terms.

Evidence, organizations & history →

Following saves this topic to your account. It does not send email or push notifications.

Evidence & reading

Public sources checked for this edition. Linked pages may subsequently change.

  1. BNT113 AHEAD-MERIT Phase 2/3 trial update ↗BioNTech · 2026-10-13

READER DISCUSSION

What does this change for you?

A question, a different reading, or a source we should consider. A short comment is welcome.

Comments are public only after editorial review. Comments, likes and reports are for people aged 18 or older. Sign-in is required; you choose a public display name. Reviews are not continuous. Discussion rules

Loading discussion…

Also in this issue

Contents →